REGN – regeneron pharmaceuticals, inc. (US:NASDAQ)

News

Regeneron (REGN) Is Up 5.4% After New Myeloma Data And Gene Writing Tie-Up With Tessera [Yahoo! Finance]
2 Reasons to Buy Regeneron Stock Like There's No Tomorrow [Yahoo! Finance]
Regeneron Pharmaceuticals (NASDAQ:REGN) had its price target raised by analysts at Morgan Stanley from $767.00 to $768.00. They now have an "equal weight" rating on the stock.
Biohaven jumps on early-stage data for antibody drug conjugate combo [Seeking Alpha]
3 Low-Volatility Stocks We're Skeptical Of [Yahoo! Finance]
Show more
Live Event: Join our next subscriber-only event: "The Data Driven Investor"
Register for our next upcoming LIVE training session, which will be hosted on Tuesday April 24th at 08:00 PM EST (New York Time).
Get your questions answered during the Q & A session.
For any support questions, contact our team: support@newsquantified.com